Title |
Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
|
---|---|
Published in |
OncoTargets and therapy, April 2017
|
DOI | 10.2147/ott.s124008 |
Pubmed ID | |
Authors |
Lars M Wagner, Val R Adams |
Abstract |
While remarkable advances have been made in the treatment of pediatric leukemia over the past decades, new therapies are needed for children with advanced solid tumors and high-grade brain tumors who fail standard chemotherapy regimens. Immunotherapy with immune checkpoint inhibitors acting through the programmed cell death-1 (PD-1) pathway has shown efficacy in some chemotherapy-resistant adult cancers, generating interest that these agents may also be helpful to treat certain refractory pediatric malignancies. In this manuscript we review current strategies for targeting the PD-1 pathway, highlighting putative biomarkers and the rationale for investigation of these drugs to treat common pediatric tumors such as sarcoma, neuroblastoma, and high-grade glioma. We summarize the completed and ongoing clinical trial data available, and suggest potential applications for further study. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 1 | 1% |
Unknown | 98 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 14 | 14% |
Researcher | 11 | 11% |
Student > Ph. D. Student | 10 | 10% |
Student > Postgraduate | 9 | 9% |
Student > Master | 9 | 9% |
Other | 19 | 19% |
Unknown | 27 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 35 | 35% |
Biochemistry, Genetics and Molecular Biology | 12 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
Agricultural and Biological Sciences | 5 | 5% |
Immunology and Microbiology | 3 | 3% |
Other | 9 | 9% |
Unknown | 30 | 30% |